Cargando…

The JAK2 GGCC (46/1) Haplotype in Myeloproliferative Neoplasms: Causal or Random?

The germline JAK2 haplotype known as “GGCC or 46/1 haplotype” (haplotype(GGCC_46/1)) consists of a combination of single nucleotide polymorphisms (SNPs) mapping in a region of about 250 kb, extending from the JAK2 intron 10 to the Insulin-like 4 (INLS4) gene. Four main SNPs (rs3780367, rs10974944, r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anelli, Luisa, Zagaria, Antonella, Specchia, Giorgina, Albano, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5979434/ https://www.ncbi.nlm.nih.gov/pubmed/29641446 http://dx.doi.org/10.3390/ijms19041152

Ejemplares similares

Second Cancer Onset in Myeloproliferative Neoplasms: What, When, Why?
por: Cumbo, Cosimo, et al.
Publicado: (2022)

SETBP1 dysregulation in congenital disorders and myeloid neoplasms
por: Coccaro, Nicoletta, et al.
Publicado: (2017)

The Contribution of JAK2 46/1 Haplotype in the Predisposition to Myeloproliferative Neoplasms
por: Paes, Jhemerson, et al.
Publicado: (2022)

The Role of NLRP3, a Star of Excellence in Myeloproliferative Neoplasms
por: Parciante, Elisa, et al.
Publicado: (2023)

IRF4 expression is low in Philadelphia negative myeloproliferative neoplasms and is associated with a worse prognosis
por: Cumbo, Cosimo, et al.
Publicado: (2021)

Next-Generation Sequencing in Acute Lymphoblastic Leukemia
por: Coccaro, Nicoletta, et al.
Publicado: (2019)

Monosomal karyotype in myeloid neoplasias: a literature review
por: Anelli, Luisa, et al.
Publicado: (2017)

Dysregulation of miRNA in Leukemia: Exploiting miRNA Expression Profiles as Biomarkers
por: Anelli, Luisa, et al.
Publicado: (2021)

The Pleiotropic Role of Retinoic Acid/Retinoic Acid Receptors Signaling: From Vitamin A Metabolism to Gene Rearrangements in Acute Promyelocytic Leukemia
por: Conserva, Maria Rosa, et al.
Publicado: (2019)

Evaluation of the association between the JAK2 46/1 haplotype and chronic myeloproliferative neoplasms in a Brazilian population
por: Silva, Sarah Pagliarini- e-, et al.
Publicado: (2013)

HMGA Proteins in Hematological Malignancies
por: Minervini, Angela, et al.
Publicado: (2020)

TP53 in Myelodysplastic Syndromes: Recent Biological and Clinical Findings
por: Cumbo, Cosimo, et al.
Publicado: (2020)

Molecular Complexity of Diffuse Large B-Cell Lymphoma: Can It Be a Roadmap for Precision Medicine?
por: Coccaro, Nicoletta, et al.
Publicado: (2020)

Digital PCR: A Reliable Tool for Analyzing and Monitoring Hematologic Malignancies
por: Coccaro, Nicoletta, et al.
Publicado: (2020)

RARG Gene Dysregulation in Acute Myeloid Leukemia
por: Conserva, Maria Rosa, et al.
Publicado: (2019)

SETBP1 and miR_4319 dysregulation in primary myelofibrosis progression to acute myeloid leukemia
por: Albano, Francesco, et al.
Publicado: (2012)

Can the New and Old Drugs Exert an Immunomodulatory Effect in Acute Myeloid Leukemia?
por: Tarantini, Francesco, et al.
Publicado: (2021)

Inside the biology of early T-cell precursor acute lymphoblastic leukemia: the perfect trick
por: Tarantini, Francesco, et al.
Publicado: (2021)

Nanopore Sequencing in Blood Diseases: A Wide Range of Opportunities
por: Minervini, Crescenzio Francesco, et al.
Publicado: (2020)

Single-Cell Sequencing: Ariadne’s Thread in the Maze of Acute Myeloid Leukemia
por: Redavid, Immacolata, et al.
Publicado: (2022)

Epitranscriptomics in Normal and Malignant Hematopoiesis
por: Minervini, Crescenzio Francesco, et al.
Publicado: (2020)

Non random distribution of genomic features in breakpoint regions involved in chronic myeloid leukemia cases with variant t(9;22) or additional chromosomal rearrangements
por: Albano, Francesco, et al.
Publicado: (2010)

Exploring the Potential of Eltrombopag: Room for More?
por: Tarantini, Francesco, et al.
Publicado: (2022)

Feasibility of Optical Genome Mapping in Cytogenetic Diagnostics of Hematological Neoplasms: A New Way to Look at DNA
por: Coccaro, Nicoletta, et al.
Publicado: (2023)

Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances
por: Cumbo, Cosimo, et al.
Publicado: (2020)

Gene expression profiling of chronic myeloid leukemia with variant t(9;22) reveals a different signature from cases with classic translocation
por: Albano, Francesco, et al.
Publicado: (2013)

Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies
por: Passamonti, Francesco, et al.
Publicado: (2011)

Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis
por: Loscocco, Giuseppe G., et al.
Publicado: (2022)

Mouse models of myeloproliferative neoplasms: JAK of all grades
por: Li, Juan, et al.
Publicado: (2011)

Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview
por: de Freitas, Renata Mendes, et al.
Publicado: (2015)

JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders
por: Vainchenker, William, et al.
Publicado: (2018)

Modification of the Histone Landscape with JAK Inhibition in Myeloproliferative Neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2020)

JAK2 in Myeloproliferative Neoplasms: Still a Protagonist
por: Bader, Michael Stephan, et al.
Publicado: (2022)

Skin lesions in chronic myeloid leukemia patients during dasatinib treatment
por: Tarantini, Francesco, et al.
Publicado: (2019)

5′RUNX1-3′USP42 chimeric gene in acute myeloid leukemia can occur through an insertion mechanism rather than translocation and may be mediated by genomic segmental duplications
por: Zagaria, Antonella, et al.
Publicado: (2014)

The JAK2 gene as a protagonist in chronic myeloproliferative neoplasms
por: de Freitas, Renata Mendes, et al.
Publicado: (2013)

Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms
por: Sapre, Manali, et al.
Publicado: (2019)

Droplet digital PCR analysis of NOTCH1 gene mutations in chronic lymphocytic leukemia
por: Minervini, Angela, et al.
Publicado: (2016)

Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms
por: Goldin, Lynn R, et al.
Publicado: (2009)

JAK2 Exon 14 Deletion in Patients with Chronic Myeloproliferative Neoplasms
por: Ma, Wanlong, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_67pq26mapuijkmfb9tpkcjahmn